secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001104659-26-048997
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata appoints Dr. Daniel Gilmer to Board; option award for 51,280 shares
--------------------------------------------------------------------------

- Dr. Daniel Gilmer (39) appointed to Board effective April 24, 2026.
- He will receive an option award to purchase 51,280 shares vesting over three years.
- Non-management directors receive a cash retainer of $40,000 per year.
- Gilmer is Senior Director at Pfizer and led the U.S. launch of PAXLOVID.
- He is co-inventor of Streptococcus phage lysin exebacase (CF-301).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926048997/0001104659-26-048997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926048997/tm2610924d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-048997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer